source
- Moonwalk Biosciences raises $70M and pivots to RNAi obesity drug developmentMoonwalk Biosciences, a California biotech founded in 2024, announced a new $70 million venture funding round. The capital will support development of its first obesity drug, which uses RNA interf…
- Roivant's mosliciguat shows strong Phase 2 results, advancing to Phase 3 for PH-ILDMosliciguat, the pulmonary hypertension candidate from Roivant Sciences subsidiary Pulmovant, cut pulmonary vascular resistance by more than 56% in a Phase 2 trial of patients with PH‑ILD, surpassi…